2 min.Read

Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma

June 12, 2025

https://www.pharmamanufacturing.com/articles/2011/095

A quiet but seismic shift is underway in global pharmaceuticals. Between 2025 and 2029, several blockbuster biologics — many of them cornerstones of cancer, autoimmune, and metabolic disease care — will go off patent.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Topics

Zaynich and the $9 Billion Moment: A New Dawn for Indian Pharma?

Careers in Medical Device Companies

Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma

Free Membership Required

What’s Killing Patients? Cancer or Rigged Drug Prices?

A Tale of Two Cities: Peptides and Prescriptions

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

Topics

What’s Killing Patients? Cancer or Rigged Drug Prices?

A Tale of Two Cities: Peptides and Prescriptions

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Pharmacy of the World Pricing Paradox

Related Articles

What’s Killing Patients? Cancer or Rigged Drug Prices?

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Pharmacy of the World Pricing Paradox

Company

Headlines

What’s Killing Patients? Cancer or Rigged Drug Prices?

A Tale of Two Cities: Peptides and Prescriptions

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Newsletter